To hear about similar clinical trials, please enter your email below
Trial Title:
Prognostic Value of RXR-α in Cutaneous Squamous and Basal Cell Carcinoma
NCT ID:
NCT05550766
Condition:
Non-melanoma Skin Cancer
Conditions: Official terms:
Carcinoma, Basal Cell
Study type:
Observational
Overall status:
Unknown status
Study design:
Time perspective:
Retrospective
Summary:
Vitamin D has a crucial role in cancer control and prevention.vitamin D receptor (VDR)
and its heterodimer Retinoid X receptor (RXR) are equally important in the cell. This
ligand (vitamin D) and receptors (VDR-RXR) complex together triggers downstream DNA
damage response in the cell.
Retinoid receptors are a superfamily of nuclear receptors. The preferred receptor that
attaches to VDR is RXR, with its subunits α, β and γ. RXR α is more frequent in the skin
than other tissues, while β occurs in internal organs and γ is frequently related to
neural disorders.
the investigator hopes to assess prognosis of SCC & BCC by using RXR-α biomarker &
attempts to use it in the treatment.
Criteria for eligibility:
Study pop:
Blocks obtained from cutaneous basal and squamous cell carcinoma tissue from 50 patients.
Sampling method:
Probability Sample
Criteria:
Inclusion Criteria:
1. Squamous cell carcinoma and basal cell carcinoma.
2. Incisional & excisional biopsies.
3. All the studied cases include sufficient materials for the immunohistochemical study
4. Complete clinical data
Exclusion Criteria:
1. Patients with a history of preoperative chemotherapy and/or radiotherapy.
2. Insufficient or tiny tissue biopsies.
Gender:
All
Minimum age:
N/A
Maximum age:
N/A
Start date:
December 2022
Completion date:
December 2023
Lead sponsor:
Agency:
Sohag University
Agency class:
Other
Source:
Sohag University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05550766
